HomeBUSINESS
BUSINESS

Nichi-Iko Earns Remicade Biosimilar Nod, Picks GI-Savvy Zeria as Copromotion Ally
(Sep.28.2017)

Nichi-Iko Pharmaceutical on September 27 won Japan approval for a biosimilar version of Remicade (infliximab), which will be the first biosimilar for the company and the second follow-on for the big-seller anti-TNFα antibody. The generic major announced Zeria Pharmaceutical as a copromotion partner on the same day ...
(LOG IN FOR FULL STORY)

News Calendar